Illumina Stock Analysis (NASDAQ:ILMN)

Add to My Stocks
$166.82 $6.82 (4.26%) ILMN stock closing price Feb 27, 2017 (Closing)
Watch Robo Advisor Video of ILMN Stock Analysis
Illumina
Updated on : Feb 27, 2017
previous close
ILMN 166.8 (0%)
S&P 500 2369.8 (0%)
Closing Price On: Feb 27, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
24.5%
Sector Average:
-1.1%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
1.27B
Debt/Equity Ratio:
 0.56
Compared to the industry
Cash Flow
Operating cash flow:
$280.2M
Net Income:
$91.3M
PROS      CONS
Operating Margins
Net Margins
Cash Flow
ROIC
ROE
FCF Margin
High Debt Burden
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
ILMN PS :
10.2
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
22%
Return on Equity:
20.2%
Free Cash Flow Margin:
32.1%
Double Tap To Exit Full Screen
0:00
/

Illumina Analysis Video

421 6 2

View Illumina stock analysis video. This is our ILMN analyst opinion covering the buy and sell arguments for ILMN stock.

Illumina, Inc. Stock Rating (3.7/5)

Our Illumina stock opinion is based on fundamentals of the company. This Illumina stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ILMN stock?

  • Illumina had a healthy average operating margin of 24.5% over the last 4 quarters.
  • Net margins stood at a healthy 18% (average) for Illumina in the Trailing Twelve Months.
  • The company has an operating cash flow which is 3.1 times the net income. We see this as a positive signal.
  • Illumina generates a high return on invested capital of 22%.
  • Return On Equity (ROE) which is a measure of the company's profitability, looks great for Illumina at 20.2%.
  • The company has a healthy free cash flow margin of 32.1%.

Should you sell ILMN stock?

  • Illumina is debt laden and has a high debt/equity ratio of  0.56.
  • The ILMN stock currently trades at a PE of 49.2, which is expensive, compared to the industry average of 22.3.
  • The company is trading at a price to sales multiple of 10.2, which is higher in comparison to the Medical-Biomed-Genetics industry average of 4.7, making ILMN stock expensive.

Comments on this video and Illumina stock